What is canrenone used for?

What is Canrenone Used For?

Canrenone is primarily used as an alternative mineralocorticoid receptor antagonist to spironolactone for treating primary aldosteronism and hypertension, particularly when patients cannot tolerate spironolactone's sex steroid-related side effects like gynecomastia, erectile dysfunction, or menstrual irregularities. 1

Primary Indications

Primary Aldosteronism (Most Common Use)

Canrenone serves as an active metabolite of spironolactone with mineralocorticoid receptor blocking properties but potentially fewer antiandrogen effects 1, 2. The Endocrine Society guidelines specifically mention canrenone as an option "where available" for patients who develop intolerable side effects from spironolactone 1.

• Mechanism: Blocks aldosterone at mineralocorticoid receptors in kidneys, heart, and blood vessels 3
• Advantage over spironolactone: Lower antiandrogen activity, reducing gynecomastia (dose-related: 6.9% at <50 mg/d vs 52% at >150 mg/d with spironolactone) and sexual dysfunction 1, 4
• Clinical context: Used when bilateral adrenal hyperplasia makes surgery inappropriate, or as medical management for unilateral disease in patients who decline or cannot undergo adrenalectomy 5

Hypertension Management

Canrenone effectively reduces blood pressure, particularly as add-on therapy:

• Dosing efficacy: In the ESCAPE-IT trial, canrenone 100 mg daily reduced systolic BP by 23.68 mm Hg and diastolic BP by 12.38 mm Hg when added to ACE inhibitors/ARBs plus hydrochlorothiazide 6
• Combination therapy: Works synergistically with ACE inhibitors and ARBs by blocking non-ACE pathways of aldosterone release 3
• Resistant hypertension: Effective as add-on therapy when maximum doses of other antihypertensives fail to control BP 6

Metabolic Syndrome and Related Conditions

Canrenone demonstrates benefits beyond blood pressure control:

• Insulin resistance: Reduces fasting plasma insulin, HOMA-IR index, and improves insulin sensitivity 7
• Inflammation: Decreases high-sensitivity C-reactive protein and TNF-α 7
• Microalbuminuria: More effective than hydrochlorothiazide in reducing microalbuminuria in type 2 diabetes when combined with ACE inhibitors or ARBs 4

Heart Failure with Preserved Ejection Fraction

The COFFEE-IT study showed canrenone reduced cardiovascular mortality over 10 years in patients with chronic heart failure and preserved systolic function 8. Patients treated with canrenone had:

• Lower left ventricular mass progression
• Reduced NYHA class progression
• Extended survival compared to conventional therapy 8

Ascites in Cirrhosis

European guidelines recommend anti-mineralocorticoid drugs (including canrenone or potassium canrenoate) as mainstay treatment for ascites in cirrhosis, with maximum dosage of 400 mg/day 9. The slow onset of action (requiring 72 hours before dose adjustment) reflects the mechanism involving aldosterone pathway exhaustion 9.

Important Clinical Considerations

Monitoring Requirements

• Potassium levels: Risk of hyperkalemia, especially with concurrent ACE inhibitors/ARBs, NSAIDs, or in CKD stage 3+ 1, 10
• Renal function: Creatinine may increase slightly (clinically non-significant in most cases) 6
• Avoid in stage IV CKD due to hyperkalemia risk 1

Drug Interactions

• NSAIDs/aspirin: Block renal tubule secretion of canrenone, reducing diuretic effect 11
• Indomethacin: Increases hyperkalemia risk 11
• Digoxin: Spironolactone (and likely canrenone) reduces digoxin clearance 11

Availability Caveat

Canrenone and its water-soluble congener potassium canrenoate are not universally available and are used "where available" according to guidelines 1, 2. They are available in only a few countries 4, which limits their use compared to the more widely available spironolactone and eplerenone.

Comparative Effectiveness

While canrenone offers better tolerability than spironolactone regarding sexual side effects, spironolactone remains first-line due to extensive evidence, wider availability, and potentially greater BP-lowering efficacy at equivalent doses 1, 5, 1. Eplerenone is the preferred alternative in most guidelines when spironolactone is not tolerated, as it has broader regulatory approval and more robust clinical trial data 5, 10.